Antimicrobial Resistance Rallies Calls For Active FDA, R&D Incentives
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With the growing problem of antimicrobial resistance putting the spotlight on the need for novel antibiotics, FDA has opened the debate on whether incentives, similar to the orphan drug system, are needed to prompt R&D in the area. But at a recent workshop on the issue, advocacy groups suggested that any such incentives need to be partnered with a more active role on the part of FDA.
You may also be interested in...
Swiss approve ceftobiprole
Swissmedic approves Basilea/Johnson & Johnson's ceftobiprole Nov. 13 to treat complicated skin and soft tissue infections, including diabetic foot infections. Already marketed in Canada as Zeftera, the novel broad-spectrum anti-MRSA cephalosporin antibiotic will be marketed in Switzerland as Zevtera. FDA recently accepted Basilea/J&J's response to an "approvable" letter for the compound in the U.S. for the same indication, giving the NDA a Class 2 designation, which means a six-month review (1Pharmaceutical Approvals Monthly May 2008, p. 6). On Nov. 18-20, FDA's Anti-Infective Drugs Advisory Committee is scheduled to discuss non-inferiority margins for CSSI studies and NDAs for possible competitors in the space, Theravance's telavancin and Arpida AG's iclaprim
Dalbavancin Delay: Pfizer Pulls NDA To Conduct Extra Phase III Trial
Additional study for the antibiotic will take 18 months to complete, company says
Dalbavancin Delay: Pfizer Pulls NDA To Conduct Extra Phase III Trial
Additional study for the antibiotic will take 18 months to complete, company says